Modality
Vaccine
MOA
PI3Ki
Target
CFTR
Pathway
Notch
Dravet
Development Pipeline
Preclinical
Feb 2019
PreclinicalCurrent
NCT06005558
156 pts·Dravet
2019-02→TBD·Not yet recruiting
156 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Preclinical
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06005558 | Preclinical | Dravet | Not yet recr... | 156 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 |